DKFZ

New T-FINDER Platform Provides Deep Insights Into T Cell Responses Against Novel Cancer Vaccine

Retrieved on: 
Tuesday, February 6, 2024

The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.

Key Points: 
  • The identification of such cancer-specific antigens and the TCRs that bind them underlies current efforts to develop targeted cancer therapies.
  • Dr. John M. Lindner and his research team at the BioMed X Institute in Heidelberg designed the T-FINDER platform to solve this problem.
  • This work provides key insights into the mechanism of anti-tumor T cell responses in these patients and will support ongoing vaccination studies.
  • "Previously, we have been limited in the tools we could use to study class II-presented epitopes such as mutant H3.

Datadobi Caps Off 2023 with Groundbreaking Innovations and Strategic Milestones in Unstructured Data Management

Retrieved on: 
Thursday, February 1, 2024

Datadobi , a global leader in vendor-neutral unstructured data management, today announced the successful close of 2023.

Key Points: 
  • Datadobi , a global leader in vendor-neutral unstructured data management, today announced the successful close of 2023.
  • - Datadobi Announced Enhancements to StorageMAP for the Most Comprehensive Unstructured Data Management at Massive Scale - With StorageMAP, users can now minimize risk while transforming unstructured data from a cost center into a profit-generating competitive advantage.
  • - The German Cancer Research Center Enhanced Data Management and Security with Datadobi - DKFZ now leverages StorageMAP to manage its unstructured data and provide availability and protection.
  • - Datadobi Named to 2023 CRN® Storage 100 List - StorageMAP named in the Data Management, Protection, and Resilience category.

Pure Storage Drives Global Customer Breakthroughs with Enterprise-Scale AI Initiatives

Retrieved on: 
Monday, November 13, 2023

SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world's most advanced data storage technology and services, today further strengthened its portfolio for artificial intelligence (AI) use cases and continued customer momentum across global AI deployments. Among the first enterprise data storage vendors to receive the NVIDIA DGX BasePOD certification, and now delivering with Cisco, new Cisco Validated Designs for FlashStack for AI, Pure Storage continues to provide enterprises with efficient, reliable access to data in support of new AI applications, underpinning modern, scalable business outcomes.

Key Points: 
  • With NVIDIA DGX BasePOD certification and expanded enterprise AI solutions, Pure Storage delivers simplified and efficient AI-ready storage infrastructure
    SANTA CLARA, Calif., Nov. 13, 2023 /PRNewswire/ -- Pure Storage® (NYSE: PSTG), the IT pioneer that delivers the world's most advanced data storage technology and services, today further strengthened its portfolio for artificial intelligence (AI) use cases and continued customer momentum across global AI deployments.
  • Powering the most advanced AI projects globally, Pure Storage empowers customers to launch AI initiatives at any scale, providing a flexible data storage foundation that grows as needs evolve.
  • Critical advancements to the Pure Storage portfolio include:
    AIRI®: Pure Storage has been at the forefront of optimized AI storage since the launch of FlashBlade® in 2017 and AIRI, its AI-Ready Infrastructure reference architecture co-developed with NVIDIA, in 2018.
  • Pure Storage offers the efficient, high performance storage platform required for AI that is automated, future-proof, and adaptable to evolving needs, catering to a broad spectrum of high-performance AI requirements.

Bicycle Therapeutics Reports Second Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, August 3, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the second quarter ended June 30, 2023 and provided recent corporate updates.
  • Our clinical programs remain on track for us to provide updates in the second half of 2023.
  • In addition, the company also received gross proceeds from Bicycle’s at-the-market (ATM) offering program during the second quarter of 2023 totaling $12.5 million.
  • In June 2023, Bicycle announced the appointment of Alethia Young as its new Chief Financial Officer, effective July 17.

The German Cancer Research Center Enhances Data Management and Security with Datadobi

Retrieved on: 
Wednesday, July 12, 2023

Datadobi ®, the global leader in unstructured data management, today announced that The German Cancer Research Center ( DKFZ ), the largest biomedical research institute in Germany, has deployed its StorageMAP platform to strengthen its data management and security capabilities.

Key Points: 
  • Datadobi ®, the global leader in unstructured data management, today announced that The German Cancer Research Center ( DKFZ ), the largest biomedical research institute in Germany, has deployed its StorageMAP platform to strengthen its data management and security capabilities.
  • "Over the years, we have worked with Datadobi and deployed their software for continuous data management, including data migration and filer archiving," said Reber.
  • "We are thrilled to have partnered with the German Cancer Research Center (DKFZ) to enhance their data management and security capabilities.
  • In related news, Datadobi announced the launch of StorageMAP 6.5, designed to support high-performance data archival and data movement of large subsets of file data.

The Mark Foundation for Cancer Research Appoints Two New Members to Board of Directors

Retrieved on: 
Wednesday, May 10, 2023

NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors. Nicola Mendelsohn CBE, Head of Global Business at Meta, and Otmar Wiestler, MD, President of the Helmholtz Association, Germany's largest scientific organization, were elected at The Mark Foundation's April board meeting. Their terms are effective immediately. Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.

Key Points: 
  • Nicola Mendelsohn CBE, Head of Global Business Group at Meta, and Otmar Wiestler, President of Helmholtz Association, join board of global leader in cancer research funding
    NEW YORK, May 10, 2023 /PRNewswire/ -- The Mark Foundation for Cancer Research announced today the appointment of two new members to its Board of Directors.
  • Both new board members are well-positioned and uniquely qualified to support the Foundation's mission of accelerating research that will transform the prevention, diagnosis, and treatment of cancer.
  • "We are honored to welcome these distinguished members to The Mark Foundation Board of Directors," said Ray DuBois, MD, PhD, Executive Chairman.
  • "The Mark Foundation is committed to accelerating cancer research on a global scale; since 2017 they have funded outstanding grantees in 13 countries," said Otmar Wiestler.

Bicycle Therapeutics Reports First Quarter 2023 Financial Results and Provides Corporate Update

Retrieved on: 
Thursday, May 4, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today reported financial results for the first quarter ended March 31, 2023 and provided recent corporate updates.
  • “The beginning of 2023 has been impactful for Bicycle and our platform,” said Kevin Lee, Ph.D., Chief Executive Officer of Bicycle Therapeutics.
  • This represents the third pillar of our oncology strategy beyond our Bicycle toxin conjugate (BTC™) and Bicycle tumor-targeted immune cell agonist® (Bicycle TICA™) programs.
  • In March 2023, Bicycle announced a strategic collaboration with Novartis to collaborate on the discovery, development and commercialization of BRCs for multiple undisclosed oncology targets.

Bicycle Therapeutics Announces Collaboration With the German Cancer Research Center, to Discover and Develop Wholly Owned Bicycle® Radio Conjugates for a Range of Oncology Targets

Retrieved on: 
Thursday, May 4, 2023

Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a collaboration with the German Cancer Research Center (DKFZ), to develop and discover Bicycle® radio conjugates (BRCs) for a range of oncology targets.

Key Points: 
  • Bicycle Therapeutics plc (NASDAQ: BCYC), a biotechnology company pioneering a new and differentiated class of therapeutics based on its proprietary bicyclic peptide (Bicycle®) technology, today announced that it has entered into a collaboration with the German Cancer Research Center (DKFZ), to develop and discover Bicycle® radio conjugates (BRCs) for a range of oncology targets.
  • Bicycle and DKFZ have been collaborating on tumor targeting BRCs which in preclinical studies, have shown superior tumor uptake compared to antibody-based approaches.
  • Results from the preclinical study were published in Cancer Research in February 2019 and can be accessed here .
  • Professor Matthias Eder commented that he and his colleagues at DKFZ were excited to work with Bicycle to develop novel radiopharmaceutical therapies.

OmniSpirant and EVerZom Team up to Develop a New Gene Therapy Treatment for Lung Cancer With Extracellular Vesicles

Retrieved on: 
Tuesday, December 6, 2022

OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a 12.8 million lung cancer project funded by Horizon Europe.

Key Points: 
  • OmniSpirant Limited and EVerZom are delighted to announce the launch of INSPIRE, a 12.8 million lung cancer project funded by Horizon Europe.
  • Over the next 3 years of the project, this world-class consortium will progress the development of a regenerative gene therapy as a transformative new treatment for lung cancer.
  • The INSPIRE programme aims to make an important and tangible impact on Europes Beating Cancer Plan and the EU Mission on Cancer.
  • The overall 5-year survival rates for people with lung cancer remain extremely poor, highlighting the desperate need for innovative treatments.

BGV appoints Elena Ritsou as Venture Partner and Andree Blaukat as Senior Advisor

Retrieved on: 
Tuesday, November 8, 2022

Amsterdam, The Netherlands 8 November 2022 BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, today announces the appointments of Dr. Elena Ritsou as Venture Partner and Dr. Andree Blaukat as Senior Advisor, further expanding its team, network and expertise in company creation and building.

Key Points: 
  • Amsterdam, The Netherlands 8 November 2022 BioGeneration Ventures (BGV), a leading early-stage VC in European biopharma, today announces the appointments of Dr. Elena Ritsou as Venture Partner and Dr. Andree Blaukat as Senior Advisor, further expanding its team, network and expertise in company creation and building.
  • Dr. Andree Blaukat, newly appointed Senior Advisor at BGV added: BGV has one of the leading most experienced early-stage life sciences venture teams in Europe.
  • Dr. Elena Ritsou, newly appointed Venture Partner at BGV commented: Europe has been particularly strong in life sciences innovation and the industry is expanding and maturing fast.
  • Edward Van Wezel, Managing Partner at BGV noted: Both Elena and Andree are experienced leaders in the life sciences industry.